当前位置: X-MOL 学术J. Am. Acad. Dermatol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Immune checkpoint inhibitors and the development of granulomatous reactions.
Journal of the American Academy of Dermatology ( IF 13.8 ) Pub Date : 2018-08-06 , DOI: 10.1016/j.jaad.2018.07.051
Christine M Cornejo 1 , Paul Haun 1 , Joseph English 2 , Misha Rosenbach 1
Affiliation  

Immune checkpoint inhibitors (ICPIs) have emerged as a frontline treatment for a growing list of malignancies. Disruption of the negative regulatory immune checkpoints by ICPIs has been associated with many immune-related adverse events. Granulomatous reactions, such as sarcoidosis-like reactions, granulomatous panniculitis, granuloma annulare, and granulomatous dermatitis, are uncommon but increasingly recognized immune-related adverse events seen in patients treated with ICPIs. The frequency and significance of these eruptions, including whether they portend responsiveness to treatment, remain unclear. Additionally, understanding the role of immune checkpoint blockade in these reactions may provide mechanistic insight into the relevant signaling pathways involved in sarcoidosis and other granulomatous disorders.

中文翻译:

免疫检查点抑制剂和肉芽肿反应的发展。

免疫检查点抑制剂(ICPIs)已经成为越来越多的恶性肿瘤的一线治疗方法。ICPI对阴性调节免疫检查点的破坏与许多与免疫相关的不良事件有关。肉芽肿样反应,如结节病样反应,肉芽肿性脂膜炎,环状肉芽肿和肉芽肿性皮炎,是罕见的,但在接受ICPI治疗的患者中,免疫相关的不良事件越来越多。这些爆发的频率和重要性,包括它们是否预示着对治疗的反应性,仍不清楚。此外,了解免疫检查点阻滞在这些反应中的作用可能会为结节病和其他肉芽肿性疾病所涉及的相关信号通路提供机制方面的见解。
更新日期:2019-10-12
down
wechat
bug